Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors

NCT02721641 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02721641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02721641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
June 30, 1999
Completion date
February 28, 2015
Enrollment
69 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms